The Role of HDACs as Leukemia Therapy Targets using HDI
-
Ahmad Ahmadzadeh
,
Elahe Khodadi
,
Mohammad Shahjahani
,
Jessika Bertacchini
,
Tina Vosoughi
,
Najmaldin Saki
Abstract
Histone deacetylases (HDACs) are the enzymes causing deacetylation of histone and non-histone substrates. Histone deacetylase inhibitors (HDIs) are a family of drugs eliminating the effect of HDACs in malignant cells via inhibition of HDACs. Due to extensive effects upon gene expression through interference with fusion genes and transcription factors, HDACs cause proliferation and migration of malignant cells, inhibiting apoptosis in these cells via tumor suppressor genes. Overexpression evaluation of HDACs in leukemias may be a new approach for diagnosis of leukemia, which can present new targets for leukemia therapy. HDIs inhibit HDACs, increase acetylation in histones, cause up- or downregulation in some genes and result in differentiation, cell cycle arrest and apoptosis induction in malignant cells via cytotoxic effects. Progress in identification of new HDIs capable of tracking several targets in the cell can result in novel achievements in treatment and increase survival in patients. In this review, we examine the role of HDACs as therapeutic targets in various types of leukemia as well as the role of HDIs in inhibition of HDACs for treatment of these malignancies.
Garcia-Manero G, Assouline S, Cortes J, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.blood.2008;112: 981- 89.
Sonnemann J, Gruhn B, Wittig S, et al. Increased activity of histone deacetylases in childhood acute lymphoblastic leukemia and acute myeloid leukemia: support for histone deacetylase inhibitors as antileukaemic agents. Br J Haematol. 2012; 158: 662-76.
Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol.2007;1:9-25.
Mummery A, Narendran A, Y. Lee K, et al. Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia. Curr Cancer Drug. 2011;11; 882-93.
Gao S M, Chen C, Wang L, et al. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasm. Exp Hematol. 2013;41:261–70.
Masetti R, Serravalle S, Biagi C, et al. The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias. J Biomed Biotechnol. 2001; 10: 1-9.
Lin R J, Sternsdorf T, Tini M, et al. Transcriptional regulation in acute promyelocytic leukaemia. Oncogene. 2001; 20:7204-16.
Wang J, Hoshino T, Redner R L, et al .ETO, fusion partner in t(8;21) acute myeloid leukemia represses transcription by interaction with the human N- CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci. 1998; 95:10860-65.
Dokmanovic M, Clarke C, Marks PA, et al. Histone Deacetylase Inhibitors: Overview and Perspectives. Mol Cancer Res. 2007; 5: 981-989.
Tsapis M, Lieb M, Manzo F, et al. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. IJBCB. 2007; 39:1500-9.11.
Iizuka M, Smith M. Functional consequences of histone modifications. Curr Opin Genet Dev. 2003; 13:154-60
Lin HY, Chen CS, Lin SP, et al. Targeting histone deacetylase in cancer therapy. Med Res Rev. 2006; 26:397-413.
Vaquero A, Scher M, Lee D, et al. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell.2004; 16: 93-105.
Yeung F, Hoberg J E, Ramsey C S, et al. Modulation of NF-kappaB dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004; 23: 2369-80.
Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2 (SIRT1)functions as an NAD-dependent p53 deacetylase. Cell. 2001; 107:149-59.
Dransfeld C L, Schaich M, Ho AD, et al. Class I HDAC SNP analysis in healthy donors compared to AML patients. Leukemia.2007; 21:1587-90.
Robertson K D, Wolffe AP. DNA methylation in health and disease. Nat Rev Genet. 2000; 1:11-19.
Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3:415- 28.
Senese S, Zaragoza K, Minardi S, et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol. 2007; 27:4784-95.
Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Letters. 2009; 280:168- 76.
Moreno DA, Scrideli AC, Abdala Cortez MA, et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia. Br J Haematol.2010; 10: 150: 665-73.
Karagianni P, Wong J. HDAC3: taking the SMRT- NCoRrect road to repression. Oncogene. 2007; 26: 5439- 49.
Jung JH, Jeong SJ, Kim JH, et al. Inactivation of HDAC3 and STAT3 is Critically Involved in 1-Stearoyl-sn-Glycero- 3-Phosphocholine-Induced Apoptosis in Chronic Myelogenous Leukemia K562 Cells. Cell Biochem Biophys. 2013; 67:1379-89.
Gao SP, Bromberg JF. Touched and moved by STAT3. Sci Signal. 2006; 330-43.
Gupta M, Han JJ, Stenson M, et al. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia. 2012; 26: 1356-64.
Gruhn B, Naumann T, Gruner D, et al. The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia. Leukemia Research. 2013; 37: 1200- 07.
Haberland M, Montgomery RL, Olson EN, et al. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet .2009; 10:32-42.
Holleman A, Cheok MH, den Boer ML, et al. Gene- expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004; 351:533-42.
Qian DZ, Kachhap SK, Collis S Jl, et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 2006; 66:8814-21.
Hackanson B, Rimmele L, Benkißer M, et al. HDAC6 as a target for anti leukemic drugs in acute myeloid leukemia. Leukemia Research.2012; 36:1055-62.
Schemies J, Sippl W, Jung M, et al. Histone deacetylase inhibitors that target tubulin. Cancer Lett. 2009; 280:222-32.
Eklund EA, Platanias LC. Inhibition of histone deacetylase 6 as a therapeutic strategy for acute lymphocytic leukemia. Leuk Lymphoma. 2011; 52:1421-22.
Simms-Waldrip T, Rodriguez-Gonzalez A, Lin T, et al. Targeting the aggresome pathway in hematologic malignancies. Mol Genet Metab. 2008; 94:283-86.
Hideshima T, Bradner JE, Wong J, et al. Small- molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci .2005; 102:8567-72.
Boyault C, Zhang Y, Fritah S, et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev. 2007; 21:2172-81.
Chengzhuo Gao, Xiwen Cheng, Minh Lam, et al. Signal-dependent Regulation of Transcription by Histone Deacetylase 7 Involves Recruitment to Promyelocytic Leukemia Protein Nuclear Bodies. Mol Biol Cell.2008; 19, 3020-27.
Chang S, Young BD, Li S, et al. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell. 2006:126, 321-334.
Block GJ, Eskiw CH, Dellaire G, et al. Transcriptional regulation is affected by subnuclear targeting of reporter plasmids to PML nuclear bodies. Mol Cell Biol. 2006; 26, 8814-25.
Moreno DA, Scrideli CA, Abdala Corte MA, et al. Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukemia. Br J Haematol.2010; 150, 665- 73.
Satyaraj E, Storb U. Mef2 proteins, required for muscle differentiation, bind an essential site in the Ig lambda enhancer. J Immunol.1998; 161, 4795-4802.
Kato H, Tamamizu-Kato S, Shibasaki F, et al. Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity. J Biol Chem. 2004; 279, 41966-74.
Damme M Van, Crompot E, Meuleman N, et al. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics.2012; 12: 1403-12.
Zhu C, Chen Q, Xie Z, et al. The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc. J Mol Med. 2011; 89:279-89.
Li L, Wang L, Wang Z, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell. 2012; 21: 266-81.
Kozako T, Aikawa A, Shoji T, et al. High expression of the longevity gene product SIRT1 and apoptosis induction by sirtinol in adult T-cell leukemia cells. Int J Cancer.2012; 131, 2044-55.
Chen WY, Bhatia R. Roles of SIRT1 in leukemogenesis. Curr Opin Hematol. 2013; 20:1-9.
Prives C, Manley JL. Why is p53 acetylated?.Cell. 2001; 107:815-18.
Nowicki MO, Falinski R, Koptyra M, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood.2004; 104:3746-53.
Chen WY, Yuan H, Wang Z, et al. De novo acquisition of BCR-ABL mutations for CML acquired resistance. INTECH. 2011: 69-84.
Chu F, Chou PM, Zheng X, et al. Control of multidrug resistance gene mdr1and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res. 2005; 65: 10183-7.
Sasaki T, Maier B, Koclega KD, et al. Phosphorylation regulates SIRT1 function. PLoS One .2008; 4020-3.
Sunami Y, Araki M, Hironaka Y, et al. Inhibition of the NAD-Dependent Protein Deacetylase SIRT2 Induces Granulocytic Differentiation in Human Leukemia Cells. PLOS ONE.2013; 8:1-12.
Gong Ke, Xie Jia, YI Hong, et al. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukemia cells. Biochem J. 2012; 443, 735-746.
Soriano AOH, Yang S. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood.2007; 110, 2302-08.
Yoshida M, Kijima M, Akita M, et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A.J Biol Chem. 1990;265:17174-9.
Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SA HA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007; 109:31- 9.
Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci. 1998; 95:3003-7.
Leoni F, Fossati G, Lewis EC, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro- inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005; 11:1-15.
Jose B, Oniki Y, Kato T, et al. Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethylketones. Bioorg Med Chem Lett. 2004; 14:5343- 6.
Rasheed WK, Johnstone RW, Prince HM, et al. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig. 2007; 16:659 -78.
Gelmon K, olcher A, Carducci M, et al. Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3_ weekly for14 days every 3 weeks in patients (pts) with advanced solid tumors. J Clin Oncol. 2005; 23:31-47.
Gui CY, Ngo L, Xu WS, et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci. 2004; 101:1241-6.
Yang H, Xu W, Li Y, et al. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest. Anti-Cancer Drugs. 2014; 25: 767-77.
Dokmanovic M, Perez GW X, Ngo L, et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther. 2007; 6:2525- 34.
Bolden JE, Pe art MJ, Johnstone RW, et al. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5:769 - 84.
Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci. 2005; 102:673 - 8.
Xu W, Parmigiani R. Histone deacetylase inhibitors: molecular mechanism of action. Oncogene. 2007; 26:5541- 52.
Xu W, Ngo L, Perez G, et al. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci. 2006; 103:15540- 5.
Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci .2000; 97:10014-19.
XuW S, Parmigian RB, Marks PA, et al. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007; 26, 5541-52.
GlaserK B, Staver MJ, Waring JF, et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2003; 2, 151-163.
Lee JH, Park JH, Jung Y, et al. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down- regulating thymidylate synthase in human cancer cells. Mol Cancer Ther. 2006; 5, 3085-95.
Carew JS, Giles FJ, Nawrocki ST, et al. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008; 269, 7-17.
Yang, Y, Zhao Y, Liao W, et al. Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment. Neoplasia. 2009; 11, 313-24.
Kanno SI, Naoyuki M, Ayako T, et al. Involvement of p21waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells. Int J Oncol. 2012; 40: 1391-96.
Xu W, Ngo L, Perez G, et al. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci.2006; 103:15540-5.
Xuelian Xu, Chengzhi Xie, Holly E, et al. Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine- Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells. PLoS One.2011; 6:1-10.
Jain N, Rossi A, Garcia-Manero G, et al. Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol. 2009; 41:72-80.
Garber K. HDAC inhibitors overcome first hurdle. Nat Biotechnol. 2007; 25:17-19.
| Files | ||
| Issue | Vol 9, No 4 (2015) | |
| Section | Articles | |
| Keywords | ||
| Histone deacetylases Histone deacetylase inhibitors leukemia | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
